ANI Pharmaceuticals Inc.
Organization details
- Legal name
- ANI Pharmaceuticals Inc.
- Former names
- Biosante Pharmaceuticals Inc BEN Abraham Technologies Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Princeton
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ANIP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001023024
- EIN
- 58-2301143
Board of directors
-
Antonio R. Pera · DirectorSince 2023
-
David Nash · DirectorSince 2023
-
Henry O. Gosebruch · DirectorSince 2026
-
Jeanne Thoma · DirectorSince 2023
-
Matthew J. Leonard · DirectorSince 2023
-
Muthusamy Shanmugam · Director · HEAD OF R&D, COO-NOVITIUM OPSSince 2023
-
Nikhil Lalwani · Director · PRESIDENT & CEOSince 2023
-
Patrick D. Walsh · DirectorSince 2023
-
Renee P. Tannenbaum · DirectorSince 2023
-
Thomas Haughey · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.7%
-
97.8%
-
98.9%
-
99.7%
-
99.9%
Board connections
2 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
Cardiff Oncology Inc. Same sectorvia Renee P. Tannenbaum
-
Neumora Therapeutics Inc. Same sectorvia Henry O. Gosebruch
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $15,675,231
- 50 sales by 12 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 29, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −2,850 | $72.87 | $207,680 |
| Oct 15, 2026 | Nikhil Lalwani Director, Officer (PRESIDENT & CEO) | Open-market sale | −5,400 | $71.89 | $388,206 |
| Oct 13, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $73.59 | $36,795 |
| Sep 29, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −2,850 | $73.00 | $208,050 |
| Sep 15, 2026 | Nikhil Lalwani Director, Officer (PRESIDENT & CEO) | Open-market sale | −5,400 | $71.00 | $383,400 |
| Sep 14, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $70.79 | $35,395 |
| Sep 11, 2026 | Jeanne Thoma Director | Open-market sale | −1,000 | $71.53 | $71,530 |
| Aug 31, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −2,850 | $72.80 | $207,480 |
| Aug 25, 2026 | Nikhil Lalwani Director, Officer (PRESIDENT & CEO) | Open-market sale | −5,400 | $74.30 | $401,220 |
| Aug 19, 2026 | Henry O. Gosebruch Director | Grant or award | +6,662 | — | — |
| Aug 13, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $75.48 | $37,740 |
| Aug 10, 2026 | Gutwerg Ori Officer (SVP, GENERICS) | Open-market sale | −3,162 | $77.00 | $243,474 |
| Jul 29, 2026 | CAREY STEPHEN P. Officer (SVP & CFO) | Open-market sale | −2,850 | $81.36 | $231,876 |
| Jul 18, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Shares withheld for tax | −2,466 | $79.20 | $195,307 |
| Jul 13, 2026 | Cook Meredith Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | −500 | $81.84 | $40,920 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about ANI Pharmaceuticals Inc.
Who is the CEO of ANI Pharmaceuticals Inc.?
Nikhil Lalwani is ANI Pharmaceuticals Inc.'s PRESIDENT & CEO.
How many directors are on ANI Pharmaceuticals Inc.'s board?
ANI Pharmaceuticals Inc.'s board has 10 directors: Antonio R. Pera, David Nash, Henry O. Gosebruch, Jeanne Thoma, Matthew J. Leonard, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D. Walsh, Renee P. Tannenbaum and Thomas Haughey.
Are ANI Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, ANI Pharmaceuticals Inc. insiders made no open-market purchases and sold $15.7 million of shares in 50 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="ani-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.